
Can Rapamycin Improve Your Dog's Life? The TRIAD Clinical Trial Explained
ABOUT THE GUESTDr. Matt Kaeberlein is co-founder of the Dog Aging Project and President of The Dog Aging Institute Board of Directors. Matt is a leading longevity researcher and holds degrees in biochemistry and mathematics from Western Washington University, and a doctorate in Biology from MIT. In this episode, he breaks down the TRIAD (Test of Rapamycin in Aging Dogs) clinical trial—the first-ever pharmaceutical intervention designed to slow biological aging in companion dogs. Dr. Kaeberlein shares cutting-edge research on rapamycin, preliminary safety data from dogs, and what this means for the future of canine longevity and healthspan.-------------------------------------------------------WHAT YOU'LL LEARN🐕 [01:01:04] Overview of the Dog Aging Project and its two core missions💊 [01:03:15] What is rapamycin? The history and how it works as a longevity drug🧬 [01:03:59] Rapamycin's proven effects in lab animals and why it matters for dogs❤️ [01:09:36] Safety trial results: What happened when researchers tested rapamycin in 41 dogs📊 [01:10:35] Heart function improvements—echocardiogram data from the safety trials⚠️ [01:12:10] Side effects data and surprising benefits owners reported💉 [01:16:06] The Trivium Vet formulation and FDA approval in cats🔬 [01:20:26] TRIAD trial design, criteria, and what the research will measure📈 [01:22:32] Current enrollment numbers and trial progress (467 dogs screened, 309 randomized)✅ [01:24:41] How to get your dog enrolled in TRIAD-------------------------------------------------------REFERENCES📘 Urfer S.R, Kaeberlein T.L., Mailheau S., Bergman P.J., Creevy K.E., Promislow D.E.L., Kaeberlein M. (2017) A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. GeroScience 39:117-127. https://doi.org/10.1007/s11357-017-9972-z📘 Barnett, B.G., Wesselowski S.R., Gordon S.G., Saunders A.B., Promislow D.E.L., et al. (2023) A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs. Front Vet Sci. 10:1168711. https//doi.org/10.3389/fvets.2023.1168711.📘 Coleman, M., Creevy K.E., Anderson R., Reed M.J., Fajt V.R., Aicher K.M., Atiee G., et al. "Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project. GeroScience 47(3):2851-2877. https//doi.org/10.1007/s11357-024-01484-7📘 Kaberlein, M. "Is Rapamycin Dead? Deep Dive into Rapamycin Research in Laboratory Animals and Humans." Longevity Science with Matt Kaberlein. https://www.youtube.com/watch?v=0AdYtOvdVk8